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Translational relevance
Colony stimulating factor 1 receptor (CSF-1R) 
signaling has been implicated in homing of mono-
cytes to the tumor microenvironment and their 
differentiation to tumor associated macrophages 
(TAMs). TAMs induce immune suppression and 
neo-angiogenesis, facilitating tumor growth and 
metastases. Work in a mouse model of mammary 
carcinoma revealed that following exposure to 
chemotherapy, malignant cells increase expres-
sion of colony stimulating factor (ligand of 
CSF-1R) leading to recruitment of TAMs and 
chemotherapy resistance. Pexidartinib, a small 
molecule inhibitor of CSF-1R (IC50 17 nM), 
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Abstract
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of 
pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with 
weekly paclitaxel in patients with advanced solid tumors.
Patients and Methods: In part 1 of this phase Ib study, 24 patients with advanced solid tumors 
received escalating doses of pexidartinib with weekly paclitaxel (80 mg/m2). Pexidartinib was 
administered at 600 mg/day in cohort 1. For subsequent cohorts, the dose was increased 
by ⩽50% using a standard 3+3 design. In part 2, 30 patients with metastatic solid tumors 
were enrolled to examine safety, tolerability and efficacy of the RP2D. Pharmacokinetics and 
biomarkers were also assessed.
Results: A total of 51 patients reported ≥1 adverse event(s) (AEs) that were at 
least possibly related to either study drug. Grade 3–4 AEs, including anemia (26%), 
neutropenia (22%), lymphopenia (19%), fatigue (15%), and hypertension (11%), were 
recorded in 38 patients (70%). In part 1, no maximum tolerated dose was achieved and 
1600 mg/day was determined to be the RP2D. Of 38 patients evaluable for efficacy, 1 
(3%) had complete response, 5 (13%) partial response, 13 (34%) stable disease, and 17 
(45%) progressive disease. No drug–drug interactions were found. Plasma CSF-1 levels 
increased 1.6- to 53-fold, and CD14dim/CD16+ monocyte levels decreased by 57–100%.
Conclusions: The combination of pexidartinib and paclitaxel was generally well tolerated. 
RP2D for pexidartinib was 1600 mg/day. Pexidartinib blocked CSF-1R signaling, indicating 
potential for mitigating macrophage tumor infiltration.
Keywords: advanced solid tumors, colony stimulating factor receptor 1 inhibitor, paclitaxel, 
phase I trials, tumor associated macrophages
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was shown to abrogate TAM recruitment follow-
ing chemotherapy, and this was associated with a 
less suppressed immune tumor microenviron-
ment, slower tumor growth, and improved sur-
vival of study animals. Here, we present the 
results of the first-in-human phase Ib study, which 
established recommended phase II dose of pex-
idartinib in combination with paclitaxel in 
patients with advanced, treatment refractory solid 
tumors.
Introduction
CSF-1R, also known as macrophage colony-stim-
ulating factor receptor (M-CSFR) and CD115, is 
a transmembrane receptor tyrosine kinase that is 
widely expressed by monocytes, macrophages, 
granulocytes, and some tumor cells.1,2 The recep-
tor has two known ligands: colony stimulating 
factor 1 (CSF-1) and interleukin 34 (IL-34). 
Upon stimulation, CSF-1R activates intracellular 
signaling integral to the differentiation, matura-
tion, migration, and survival of monocytes and 
macrophages.3–5 In cancer, CSF-1R signaling 
facilitates recruitment and survival of TAMs 
within the tumor microenvironment, leading to 
suppression of host antitumor immunity. TAMs 
also secrete proangiogenic factors and promote 
growth and invasiveness of malignant cells.6
Several types of solid tumors (including breast, 
renal cell carcinoma, leiomyosarcoma, and epi-
thelial ovarian carcinomas) express high levels of 
CSF-1.7–11 Experiments performed in mammary 
carcinoma bearing transgenic MMTV–polyoma 
middle T (PyMT) mice demonstrated that 
expression of CSF-1 by carcinoma cells increases 
following treatment with chemotherapy. This 
increase in CSF-1 expression is then associated 
with higher proportion of TAMs and lower levels 
of CD8+ and CD4+ T lymphocytes.12
Treatment of tumor-bearing PyMT mice with a 
combination of paclitaxel and CSF-1R inhibitor 
led to blockade of macrophage recruitment to 
the tumor microenvironment and significant 
increases in CD8+ T cells. This was associated 
with CD8+ T-cell dependent reduction in tumor 
progression, metastases and improvement in sur-
vival of study animals. These preclinical data 
provided justification for therapeutic approaches 
in patients with solid tumors aimed at mitigating 
macrophage recruitment and function by inhibi-
tion of CSF-1R in combination with cytotoxic 
chemotherapy.12,13
Pexidartinib (PLX3397) is a novel, orally availa-
ble, small molecule kinase inhibitor that blocks 
CSF-1R at an IC50 of 17 nM. Furthermore, pex-
idartinib inhibits oncogenically activated FLT3 
(FLT3-ITK) and interferes with stromal cell fac-
tor-induced auto-phosphorylation of c-Kit pro-
tein (Kit) at IC50 concentrations below 1 µM. In 
addition, pexidartinib is known to inhibit differ-
entiation of osteoclast precursors in a RANK-L 
and CSF-1 dependent manner (Investigator’s 
Brochure).14
Based on the results of the above preclinical stud-
ies, we conducted a phase Ib clinical trial of pex-
idartinib in combination with weekly paclitaxel in 
patients with advanced solid tumors. The primary 
objectives were to evaluate the safety of the drug 
combination and determine the recommended 
phase II dose (RP2D). Secondary objectives 
included evaluating the potential for a drug–drug 
interaction effect on pharmacokinetic parameters 
and exploring preliminary efficacy. In addition, 
the effect of the treatment combination on periph-
eral blood CSF-1 and CD14dim/CD16+ mono-
cyte levels (potential pharmacodynamic markers 
of pexidartinib) was explored.
Materials and methods
Study population
The study recruited patients from three academic 
institutions (University of California San 
Francisco, Case Western Reserve University, and 
The Ohio State University Comprehensive 
Cancer Center). The respective institutional 
review boards have approved the study. Western 
IRB was used at OSU (WIRB # 20120818). Case 
Western Reserve University and University of 
California San Francisco used their institutional 
IRB (IRB # 062752 and 149357, respectively) 
and the study was registered with ClinicalTrials.
gov (NCT01525602). The study had three parts. 
In part 1, dose escalation of pexidartinib in com-
bination with standard dose of weekly paclitaxel 
given continuously was conducted using a 3+3 
design. In part 2, 30 patients with advanced solid 
tumors were enrolled. Part 3 has enrolled 18 
patients with platinum-resistant or -refractory 
advanced ovarian cancer. Here, we report the 
results from parts 1 and 2.
Patients in part 1 had advanced, incurable solid 
tumors. Patients in part 2 had advanced, incura-
ble solid tumors for which a taxane would be 
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considered a reasonable chemotherapy option. 
Patients were to be 18 years or older, have an 
Eastern Cooperative Oncology Group (ECOG) 
performance score (PS) of 0–2, have an antici-
pated life expectancy of at least 12 weeks, and 
adequate bone marrow reserve as well as renal, 
hepatic, and cardiac function. A washout period 
was required after any prior chemotherapy, radia-
tion, investigational, biologic, hormonal, or tar-
geted therapy. Additionally, bone-directed 
therapy was not to be started within 2 weeks prior 
to study day 1 or during the first 28 days on study 
therapy. Patients were also required to have had 
resolution of all prior treatment-related toxicities 
to grade 1 or less except for grade 2 fatigue or 
alopecia.
Patients were excluded from study participation 
if they had a secondary active malignancy, 
refractory nausea and vomiting, malabsorption, 
external biliary shunt, or significant small bowel 
resection that would preclude adequate absorp-
tion of oral pexidartinib, ongoing treatment 
with any other investigational therapy, unstable 
brain metastases requiring systemic steroid 
treatment, prior anaphylactic or severe hyper-
sensitivity reaction to paclitaxel or cremaphor-
containing agents, grade 2 or higher neuropathy, 
persistent grade 2 fatigue, or an active untreated 
infection.
Study objectives
The main objectives of part 1 were to explore the 
safety, tolerability and dose limiting toxicities of 
escalating doses of daily oral pexidartinib with 
weekly intravenous paclitaxel and to establish a 
RP2D. The main objective of part 2 was to deter-
mine the safety of pexidartinib administered at 
the RP2D in combination with paclitaxel in 
patients with advanced, nonresectable, solid 
tumors.
The secondary objectives of this study were to 
explore the efficacy of pexidartinib in combina-
tion with paclitaxel in patients with advanced 
solid tumors, and determine the pharmacokinet-
ics (PK) of pexidartinib when administered in 
combination with paclitaxel.
Exploratory objectives included correlating the 
increases in plasma CSF-1 levels and the 
decreases in blood CD14dim/CD16+ monocyte 
levels during treatment with specific dose levels 
of pexidartinib.
Dose escalation (part 1)
The study employed a traditional 3+3 design. 
Cohort 1 started treatment with oral pexidartinib 
at a dose of 600 mg/day (divided to twice daily). 
Paclitaxel at a dose of 80 mg/m2 was administered 
intravenously over 1 h once weekly (±48 h) in all 
cohorts. The cycle length was 28 days. Following 
cycle 1, the protocol permitted skipping one of four 
paclitaxel doses in each cycle per discretion of the 
treating physician. The planned pexidartinib dose 
escalation schedule is provided in Table 1.
Between three and six patients were to be enrolled 
at each dose level. Enrollment into the next higher 
dose level was to begin only if the first three 
patients enrolled into the cohort completed the 
28-day observation period without the occur-
rence of a dose-limiting toxicity (DLT). If one of 
the three initial patients at a given dose level expe-
rienced a DLT, the cohort at this dose level was 
to be expanded to include an additional three 
patients (six patients total).
If two or more out of six patients experienced a 
DLT, dose escalation was to be stopped and the 
preceding dose level was considered to be the 
maximum tolerated dose (MTD) and, therefore, 
the RP2D.
Dose-limiting toxicities
A DLT was defined as any treatment-related 
adverse event (AE) that met the criteria described 
below and occurred within the first 28 days after 
the start of combination therapy. Patients must 
have received at least 21 days of pexidartinib and 
at least three of the four planned doses of pacli-
taxel during the first 28 days to be considered 
evaluable for a DLT. Patients not meeting these 
criteria were replaced.
DLTs included hematological AEs (grade 4 neu-
tropenia lasting for ⩾7 days, grade 4 thrombocy-
topenia, and grade 3 thrombocytopenia associated 
with bleeding) and any other grade ⩾3 toxicity 
unless the event was clearly unrelated to treat-
ment with pexidartinib or paclitaxel and with the 
exclusion of the following: grade ⩾3 nausea, vom-
iting, or diarrhea, that resolved to grade ⩽2 within 
48 h with or without medical intervention or 
prophylaxis; allergic reaction to paclitaxel; grade 3 
fatigue that resolved to grade ⩽2 within 14 days; 
grade ⩾3 hyperglycemia; transient (<14 days) 
increase in LFTs of less than or equal to one 
grade in severity compared with baseline levels in 
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patients with baseline liver metastases; grade 3 
peripheral neuropathy in patients with baseline 
grade ⩾1 peripheral neuropathy or a history of 
chemotherapy-associated peripheral neuropathy; 
grade 3 myalgia or arthralgia in patients with base-
line grade ⩾1 myalgia or arthralgia; or grade 3 rash 
for which symptoms were easily managed with 
supportive care and there was no evidence of 
superinfection or limitation of self-care activities.
Pharmacokinetics
A noncompartmental method of analysis was 
used to analyze the plasma concentrations of pex-
idartinib. The Cmax, Tmax, and a partial AUC 
(AUC0-4) at steady state were determined using 
samples taken on cycle 1, day 15. Plasma concen-
trations of paclitaxel were also determined in 
parallel.
Statistical analyses
Safety and tolerability were evaluated from the 
results of reported signs and symptoms, sched-
uled and symptom-directed physical examina-
tions, vital sign measurements, 12 lead ECGs 
(including QTcF intervals), and clinical labora-
tory test results. The safety population included 
patients who received at least one dose of study 
drug. AEs were recorded from the time the patient 
received the first dose of study drug up to 28 days 
after the last dose, or prior to start of new antitu-
mor therapy, whichever occurred first.
AEs were summarized descriptively by attribu-
tion of study therapy (unlikely, probably, likely, 
and definitely related) and grade using Common 
Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. Laboratory variables were summa-
rized using mean change in value from baseline 
to scheduled time points for each dose level 
group and 95% confidence interval. Laboratory 
values were also categorized according to their 
CTCAE version 4 toxicity grade and tabulated 
by worst on-study toxicity grade and dose 
level group. Concomitant medications were 
also summarized.
Response to treatment according to RECIST ver-
sion 1.1 criteria was summarized descriptively by 
dose level. The duration of response was calcu-
lated for each patient with a response to therapy. 
The duration of response was defined as number 
of days from the date of initial response (con-
firmed at least 28 days later) to the date of first 
documented disease progression or death, which-
ever occurred first.
Pexidartinib and paclitaxel pharmacokinetic 
parameters were analyzed based on their plasma 
concentrations using noncompartmental model 
with Phoenix, Version 6.4 (Pharsight, CA, USA). 
Table 1. Summary of dosing cohorts and dose limiting toxicities.
Dose levels Pexidartinib mg/day 
PO divided BIDc
Paclitaxel 
mg/m2 IV
Patient number 
(N = 54)
Number of DLTs (N = 2)
Cohort -1 400 80 0 0
Cohort 1a 600 80 9 0
Cohort 2 800 80 3 0
Cohort 3 1000 80 3 0
Cohort 4 1200 80 6 Grade 3 hypophosphatemia
Cohort 5b 1600 80 3 Grade 3 atrial fibrillation
Cohort 6 2000 80 0 Not applicable
Part 2 1600 80 30 0
Paclitaxel was administered intravenously over approximately 60 min on days 1, 8, 15 and 22 per 28 day cycle. Following 
cycle 1 of study therapy patients were permitted to skip 1 of 4 paclitaxel doses in each cycle.
aStarting dose level.
bRecommended phase II dose.
cBID stands for twice daily.
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Descriptive statistics were used to analyze explor-
atory pharmacodynamic endpoints. SAS 9.3 soft-
ware was used to conduct all statistical analysis.
Study oversight
An academic steering group, including represent-
atives from the sponsor (Plexxikon), designed the 
study. All the authors vouch that the study 
adhered to the protocol and confirm the accuracy 
and completeness of the data. The first author 
prepared the first draft of the manuscript with 
assistance from the sponsor. Subsequent revi-
sions and interpretation of the study data were 
completed by all authors. An institutional review 
board, at each site, approved the study and all the 
patients gave written informed consent before 
enrollment. The study was conducted according 
to the principles of Good Clinical Practice and 
the Declaration of Helsinki. A study steering 
committee reviewed the study conduct.
Results
Demographics and patient characteristics
A total of 54 patients were enrolled, 24 in part 1 
(dose escalation) and 30 in part 2 (RP2D expan-
sion). Study patients ranged from 32 to 82 years 
of age with a median of 60 years, 61% were female 
and 89% white (Table 2). The majority (65%) of 
subjects at baseline had an ECOG PS of 1 and 
28% an ECOG PS of 0. The most frequent pri-
mary tumor sites were breast and ovarian (13% 
each) and neuroendocrine (11%). Patients 
received a median of 3.5 prior lines of anticancer 
therapy (range 1–8 lines), with 80% of subjects 
having received a platinum-based therapy, and 
57% having received prior taxane therapy.
Exposure and dosing compliance
Patients were on daily oral pexidartinib for a mean 
of 70.5 days, with a range across dose levels 
from 50.8 days (600 mg) to 109.2 days (1200 mg). 
Patient compliance with pexidartinib was high, 
with 89% of the patients taking over 80% assigned 
dose; 25 (46%) patients reported missing doses of 
pexidartinib due to AEs of any cause, and 23 
(43%) patients missed doses due to noncompli-
ance. Because of an AE that was at least possibly 
related to pexidartinib, the drug was temporar-
ily withdrawn from 19 (35%) patients, and per-
manently withdrawn from 5 (9%) patients. A 
total of 14 (26%) patients had pexidartinib dose 
Table 2. Demographics and patient characteristics.
Parameter Total
(N = 54)
Age  
 Mean 58.4
 SD 11.49
 Median 60.0
 Min, Max 32, 82
Gender n (%)  
 Male 21 (39)
 Female 33 (61)
Ethnicity n (%)  
 Hispanic or Latino 3 (6)
 Not Hispanic or Latino 51 (94)
Race n (%)  
 American Indian or Alaska Native 0
 Asian 1 (2)
 Black or African American 4 (7)
 Native Hawaiian or Other Pacific 
Islander
0
 White 48 (89)
 Other 1 (2)
ECOG Status n (%)  
 0 - Fully Active 15 (28)
 1 - Restricted 35 (65)
 2 - Ambulatory 4 (7)
 3 - Limited Self Care 0
 4 - Completely Disabled 0
Primary
Malignancy (Those in ⩾10% of 
patients)
 
 Breast 7 (13)
 Ovarian 7 (13)
 Neuroendocrine 6 (11)
Prior Anticancer Therapy  
  Number of lines of therapy, median 
(range)
3.5 (1, 8)
 Prior platinum therapy n (%) 43 (79.6)
 Prior taxane therapy n (%) 31 (57.4)
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reductions; 6 patients had dose reductions as an 
immediate action following pexidartinib-related 
AE, while the remainder had pexidartinib held due 
to an AE and then restarted at a reduced dose (see 
Supplementary Table S1 for summary of actions).
The mean number of paclitaxel doses was 9.8, with 
a range across dose levels of 7.0 doses (600 mg) to 
15.5 doses (1200 mg); 39% of the patients received 
> 80% of paclitaxel dosing. However, following 
cycle 1, the study protocol permitted omitting one 
paclitaxel dose in each cycle (i.e., patients could 
receive 75% of the planned dose per cycle). Of the 
45 study patients that completed the first 28-day 
cycle, 36 (80%) received at least three paclitaxel 
doses in each full 28-day cycle. Of the 27 study 
patients who completed two or more cycles, 20 
(74%) received at least three paclitaxel doses in each 
full cycle following cycle 1 of therapy. The reasons 
for omitting paclitaxel dose were AEs (54%), physi-
cian or patient preference to omit one paclitaxel in 
each cycle (34%), disease progression (4%), and 
other (8%). Eight (15%) patients had paclitaxel dose 
reductions: seven as an immediate action following 
paclitaxel related AE, while the remaining patient 
had paclitaxel treatment interrupted and restarted at 
a reduced dose (Supplementary Table S2).
Adverse events
Treatment emergent AEs as they relate to severity 
grade, dose level, and attribution to the study 
therapy, are documented in Supplementary 
Tables S3 and S4. A detailed list of AEs occurring 
in ⩾10% of patients that were at least possibly 
related to study therapy are presented in Table 3. 
A total of 51 (94.4%) patients reported one or 
more AE, including anemia, fatigue, decreased 
appetite, diarrhea, nausea, increased AST, and 
alopecia, that was at least possibly related to 
either study drug. The most common AE was 
fatigue (65%), followed by anemia (59%), diar-
rhea, and nausea (both 39%). The most frequent 
type of AE by body system was gastrointestinal 
disorders, reported in 89% (48/54) patients, most 
of which were nausea, vomiting, and diarrhea. 
The majority of these toxicities were grade 1 and 
2 in severity.
Grade 3–4 AEs that were at least possibly related 
to study therapy were recorded in 38 patients 
(70%) with most of them representing hemato-
logic toxicities. Grade 3–4 hematological toxici-
ties occurring with a frequency ⩾10% were 
anemia (26%), neutropenia (22%), and decreased 
lymphocytes (19%). Grade 3–4 nonhematological 
toxicities occurring with a frequency ⩾10% were 
fatigue (15%) and hypertension (11%). Grade 4 
AEs occurred in five patients (9%). One patient 
died due to sudden cardiac death (grade 5), which 
was assessed by the investigator as not related to 
either study drug. Treatment was discontinued in 
six (11%) patients due to AEs. Low subject num-
bers in most cohorts did not allow for between-
cohort statistical comparison.
Elevated AST occurred in 19 (35%) patients, of 
which 14 (26%) were grade 1, 1 (2%) grade 2, 
and 4 (7%) grade 3. Elevated ALT occurred in 10 
(19%) patients, of which 6 (11%) were grade 1, 3 
(6%) grade 2, and 1 (2%) grade 3. Elevated CPK 
occurred in 17 (31%) patients, of which 12 (22%) 
were grade 1 and 5 (9%) grade 2. One patient had 
a grade 3 elevation of bilirubin. The elevation of 
transaminases and CPK is a class-specific AE 
associated with CSF1R inhibitors thought to be 
related to inhibition of Kupffer cell function in 
the liver, which is involved in clearance of these 
enzymes.20 Supplementary Tables S5 and S6 list 
toxicities that were assessed to be at least possibly 
related to either pexidartinib or paclitaxel, respec-
tively, and occurred in at least 10% of patients.
Serious adverse events
Of the 54 patients in the safety population, 17 
patients (31%) experienced 29 treatment-emer-
gent serious adverse events (SAEs). SAEs occurred 
in 1 of 9 patients (11%) in cohort 1, 1 of 3 patients 
(33%) in cohort 2, 3 of 3 patients (100%) in 
cohort 3, 2 of 6 patients (33%) in cohort 4, and 10 
of 33 patients (30%) in cohort 5 and part 2 
(RP2D). Most types of SAEs were reported in a 
single patient. The only treatment-emergent SAEs 
reported by two or more patients overall were 
tooth infection [two patients (4%), one patient 
each in cohorts 3 and 4], pyrexia [two patients 
(4%), one patient each in cohorts 1 and 5], and 
febrile neutropenia (one patient in cohort 3 and 
cohort 5/part 2). Of the 17 patients with 29 SAEs, 
12 had 17 SAEs considered related to one or both 
study drugs (2 were related to pexidartinib, 5 were 
related to paclitaxel, and 10 were related to both 
study drugs). SAEs considered to be related to 
study treatment included pyrexia, febrile neutro-
penia, tooth infection, cellulitis, abscess, puncture 
site infection, dehydration, nausea, supraventricu-
lar tachycardia, atrial fibrillation, clostridium dif-
ficile colitis, staphylococcal bacteremia, and blood 
bilirubin and blood transaminase elevation.
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Dose limiting toxicities
As listed in Table 1, two patients had AEs that 
were DLTs: one in the 1200 mg Cohort (grade 3 
hypophosphatemia) and one in the 1600 mg 
Cohort (grade 3 atrial fibrillation). However, 
expansion of the cohorts did not confirm DLT 
for these dose levels. No maximum tolerated 
dose was determined and dose escalation was 
stopped at 1600 mg/day because PK assessment 
indicated adequate exposure. Therefore, this 
dose was determined to be the RP2D for patients 
in part 2.
Table 3. Summary of toxicities that occurred in >10% of patients and were at least possibly related to either 
study drug.
Toxicity Grades 1 & 2 Grades 3 & 4 All Grades
Number (%)
Fatigue 27 (50) 8 (15) 35 (65)
Anemia 18 (33) 14 (26) 32 (59)
Neutropenia/Decreased Neutrophils 11 (20) 12 (22) 23 (43)
Diarrhea 17 (31) 4 (7) 21 (39)
Nausea 18 (33) 3 (6) 21 (39)
Aspartate Aminotransferase Increased 15 (28) 4 (7) 19 (35)
Decreased Appetite 19 (35) 0 (0) 19 (35)
Lymphocyte Count Decreased 8 (15) 10 (19) 18 (33)
White Blood Cell Count Decreased 16 (30) 2 (4) 18 (33)
Dysgeusia 17 (31) 0 (0) 17 (31)
Blood Creatine Phosphokinase Increased 17 (31) 0 (0) 17 (31)
Vomiting 13 (24) 2 (4) 15 (28)
Alopecia 15 (28) 0 (0) 15 (28)
Hypertension 7 (13) 6 (11) 13 (24)
Rash 8 (15) 3 (6) 11 (20)
Alanine Aminotransferase Increased 9 (17) 1 (2) 10 (19)
Blood Alkaline Phosphatase Increased 8 (15) 1 (2) 9 (17)
Hypophosphatasemia 3 (6) 5 (9) 8 (15)
Neuropathy Peripheral 6 (11) 2 (4) 8 (15)
Pyrexia 8 (15) 0 (0) 8 (15)
Pruritus 7 (13) 0 (0) 7 (13)
Periorbital Edema 7 (13) 0 (0) 7 (13)
Edema Peripheral 6 (11) 0 (0) 6 (11)
Constipation 6 (11) 0 (0) 6 (11)
Hypokalemia 6 (11) 0 (0) 6 (11)
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Pharmacokinetics
Average pexidartinib plasma concentration and 
exposure increased with increasing pexidartinib 
dose, and reached saturation at the 1200 mg dose 
(Figure 1a, Supplementary Table S7). Paclitaxel PK 
appeared to be nonlinear, and the plasma concentra-
tion decreased rapidly after infusion (Figure 1b).
Plasma paclitaxel PK was consistent with reports 
for single agent paclitaxel, indicating no drug–
drug interaction at steady-state pexidartinib levels 
(Figure 1b).15
Pharmacodynamic biomarkers
CSF-1 levels in plasma increased after pexidarti-
nib treatment, possibly due to the slowing of the 
internalization of ligand with its receptor, which is 
thought to be the primary mechanism of plasma 
CSF-1 clearance or the compensatory increase in 
CSF-1 expression. All pexidartinib doses tested 
showed a robust average CSF-1 increase of from 
800 to 2100% (Figure 1c).16
The percentage of CD14dim/CD16+ monocytes 
of total blood monocytes at baseline decreased by 
57% to 100% after 2 weeks of pexidartinib treat-
ment in nearly every patient, indicating blockade 
of CSF-1R signaling. This decrease was observed 
even at the 600 mg dose level (Figure 1d). The 
CD14dim/CD16+ monocyte subset is known to 
be sensitive to CSF-1 treatment, and thus serves 
as a pharmacodynamic marker of CSF-1R inhibi-
tion. Levels of CD14dim/CD16+ monocytes 
have also been correlated with increased tumor 
burden, and preliminary research has implicated 
these cells in tumor-induced suppression of host 
immune response and promotion of tumor inva-
siveness and angiogenesis.6
Antitumor activity
Table 4 provides summary of tumor response in 
38 patients evaluable for efficacy. Overall, 3% of 
patients had complete response (CR), 13% had 
partial response (PR), 34% had stable disease, and 
45% progressive disease as the best response to 
study therapy. The remaining 5% of patients could 
not be assessed or did not have confirmatory scans. 
Of the five patients who experienced partial 
response to study therapy, two had breast cancer, 
and the remaining three had rectal, bladder and 
Figure 1. Summary of pharmacokinetic and pharmacodynamics analysis: (a) pexidartinib steady-state plasma 
exposure on day 15; (b) pacilitaxel plasma concentration after IV infusion; (c) plasma CSF-1 concentration; (d) 
CD14dim/16+ monocyte levels on days 1 and 15 of study treatment.
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ovarian cancers, respectively. One patient with 
peritoneal carcinoma had CR (see below). In addi-
tion, one patient with neuroblastoma harboring a 
missense mutation V32G in the csf-1r gene was on 
study therapy for approximately 48 weeks until dis-
ease progression developed. Figure 2 is a waterfall 
diagram that summarizes the maximum percent-
age change in the size of the target lesions for 
patients in parts 1 and 2. The swimmers plot 
depicting the duration of all 54 patients on study is 
shown in Supplementary Figure S1.
Of the six patients with platinum-resistant or 
-refractory gynecologic malignancies (five with 
ovarian cancer and one with primary peritoneal 
carcinoma), one had a CR and one a PR with 
response durations of 189 and 94 days and pro-
gression free survival of 239 and 148 days, respec-
tively. All these six patients had received a taxane 
prior to study enrollment.
Other clinical parameters of interest
No significant deterioration of ECOG PS was 
observed for the majority of patients between the 
start and end of study therapy. The percentage of 
patients with ECOG PS <2 at baseline was 83% 
(49/54), and the percentage of patients with 
ECOG PS <2 at the end of treatment was 79% 
(29/37 subjects who had ECOG assessment 
reported at the end or treatment visit). Three 
patients had a decline in ECOG PS to >1. At the 
end of treatment, 14% (5/37) had an ECOG PS 
of 0 (fully active), 65% (24/37) PS 1 (restricted), 
16% (6/37) PS 2 (ambulatory), and 1 patient 
each (3%) PS of 3 and 4.
Discussion
Reprograming the tumor microenvironment as a 
potential strategy for reversing tumor-induced 
immune suppression has been gaining increasing 
interest and is supported by translational data.17 
Table 4. Summary of best overall tumor response in 
evaluable patients.
Total
(N = 38)
Complete Response 1 (3%)
Partial Response 5 (13%)
Stable Disease 13 (34%)
Clinical Benefita 19 (50%)
Progressive Disease 17 (45%)
Unable to Assess 2 (5%)
Not Evaluable 0
aClinical Benefit = Complete Response + Partial 
Response + Stable Disease.
Figure 2. Waterfall diagram of maximum percentage change in tumor size for patients in parts 1 and 2. 
Patients with at least one posttreatment radiographic assessment were included. Positive values indicate 
tumor growth, and negative values indicate tumor reduction. The upper and lower dashed lines depict 
thresholds defined in RECIST v1.1 for progressive disease and partial response, respectively.
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The CSF-1/CSF-1R axis is implicated in the 
homing of monocytes to the tumor microenvi-
ronments and their differentiation to become the 
M2 type of TAMs.3,6 M2 TAMs mediate immune 
suppression and neo-angiogenesis facilitating 
tumor growth and metastases.17,18 TAMs are 
associated with poorer patient survival, expres-
sion of immunosuppressive cytokines, and the 
switch to Th2 based immunity.14,19 In vivo stud-
ies in transgenic mouse model of mammary car-
cinoma demonstrated that TAMs increase within 
the tumor stroma after exposure to cytotoxic 
chemotherapy, and this increase mediates resist-
ance to subsequent treatment. Inhibition of 
CSF-1R function not only leads to an increase in 
cytotoxic T lymphocytes, but is also associated 
with slower tumor growth, reduction in metasta-
ses, and improved survival of tumor-bearing ani-
mals treated with chemotherapy.12 This provides 
support for clinical development of CSF-1R 
inhibition in combination with cytotoxic chemo-
therapy. Here, we report a phase Ib clinical trial 
of CSF-1R inhibitor pexidartinib (PLX3397) in 
combination with weekly paclitaxel in patients 
with treatment refractory solid tumors. The 
study demonstrated an acceptable toxicity pro-
file, with 89% of patients being able to maintain 
>80% relative dose intensity of pexidartinib and 
74% of patients being able to receive at least 3 
doses of paclitaxel therapy in each 28 day cycle 
beyond cycle 2. Fatigue (65% overall, 15% 
grade ⩾3), nausea (39%, 6% grade ⩾3), and 
diarrhea (39% overall, 7% grade ⩾3) represented 
the most common nonhematologic toxicities. 
Grade 3 anemia (59% overall, 26% grade ⩾3), 
lymphopenia (33% overall, 19% grade ⩾3), and 
neutropenia (43% overall, 22% grade ⩾3) were 
the most common hematologic toxicities. Despite 
high frequency of these events, most of these were 
easily manageable with supportive care and dose 
modifications of pexidartinib (which occurred in 
26% of patients), or temporarily withholding 
paclitaxel (occurring in 39% of patients). The 
most frequent reason for discontinuation of study 
therapy was disease progression with only six 
(11%) patients discontinuing study therapy due 
to adverse events.
Grade 1 or 2 increases in serum transaminases 
have been common with pexidartinib and other 
CSF-1R inhibitors with grade 3 or higher increases 
occurring less frequently. It has been hypothe-
sized that reversible elevations in transaminases 
as well as lactate dehydrogenase (LDH) and cre-
atinine kinase in patients receiving CSF1R 
inhibitors may be the result of inhibition of 
Kupffer cells, which are resident macrophages 
present in the sinusoids within the liver and which 
express CSF1R.20 Kupffer cells function as part 
of the mononuclear phagocytic system.21 They 
also use pinocytosis and receptor-mediated 
phagocytosis to filter blood of particulate matter 
including several enzymes such as aspartate ami-
notransferase and creatinine kinase.22 Animal 
studies demonstrated that neutralizing CSF1 or 
treatment with clodronate (known to be toxic to 
macrophages) results in decreased level of Kupffer 
cells and elevation in ALT, AST, CK, and LDH 
enzymes in the circulation.20 Furthermore, knock-
out mice for CSF1 (CSF1op/op/CSF1op/op), 
also known as osteopetrotic mice, have fewer 
Kupffer cells and higher levels of the above 
enzymes compared with wild-type littermates.
Pexidartinib may also have a more direct hepato-
toxic effect. Elevations of liver transaminases and 
bilirubin have been observed in most studies with 
single agent or combination pexidartinib regi-
mens. Based on these studies, there is a small 
subset of patients who have drug-induced liver 
injury. Possible drug-induced liver injury occurred 
in three patients receiving combination therapy of 
pexidartinib with vemurafenib (confirmed by 
liver biopsy in one patient). In each of these 
patients, the onset of liver abnormalities was 
noted within the first cycle of treatment. 
Pexidartinib was withheld for each patient, and 
over the following weeks, further increases were 
seen, predominantly in bilirubin and alkaline 
phosphatase. In one of these patients, liver biopsy 
showed changes in the biliary system with a pau-
city of bile ducts. Despite discontinuation of pex-
idartinib, bilirubin continued to increase and was 
associated with pruritus in two patients. In two 
patients, bilirubin and aminotransferases 
decreased significantly to nearly normal over the 
following 2–3 months. More data is needed to 
clarify the rate and contribution of the study drug 
to liver injury and investigate possible mechanism 
by which this occurs. Given this experience, 
future studies with pexidartinib will require care-
ful patient selection, close monitoring of liver 
function with aggressive discontinuation parame-
ters for patients who develop transaminase and 
bilirubin elevations and avoidance of other poten-
tially hepatotoxic agents.
It should be noted that pexidartinib treatment 
leads to rapid decline in CD14dim/CD16+ 
monocytes in the peripheral blood, with near 
R Wesolowski, N Sharma et al.
journals.sagepub.com/home/tam 11
complete reduction of their levels even with doses 
as low as 800 mg daily. There was also concurrent 
increase in CSF1 levels in all patients. These 
results support the use of circulating CD14dim/
CD16+ monocytes and CSF1 levels as suitable 
pharmacodynamic markers that may be useful in 
determining target occupancy and biologic effects 
of pexidartinib.
This study has some limitations. Firstly, tumor 
biopsies were not collected, and therefore we 
were unable to measure the effect of study ther-
apy on tissue levels of TAMs, tumor infiltrating 
lymphocytes (favorable prognostic factor in some 
cancers), and other immune cell subsets in the 
tumor microenvironment. Future studies should 
incorporate paired tumor biopsies in order to 
learn whether combination of pexidartinib and 
paclitaxel results in favorable changes in the 
tumor microenvironment and whether that cor-
relates with response. Secondly, the study had 
insufficient patient number to compare safety and 
efficacy of study therapy with historical control 
patients that had specific tumor types and received 
paclitaxel. This is a limitation of most solid tumor 
phase I trials, which aim at establishing the safety 
profile and a RP2D. Thirdly, the study enrolled 
patients who had history of multiple prior lines of 
therapy (range 1–8). Therefore, an objective 
response rate of 16% and clinical benefit rate of 
50% is not disappointing. Future studies may 
limit enrollment to patient populations with 
restricted number of prior therapies and focus on 
specific tumor types.
Other inhibitors of CSF-1R signaling are also in 
clinical development, such as small molecule 
inhibitors ARRY-382, PLX7486, BLZ945, and 
JNJ-40346527, as well as monoclonal antibodies 
such as LY3022855, emactuzumab, AMG820, 
cabiralizumab, MCS110, and PD-0360324 (the 
latter two are inhibitors of CSF1). However, pex-
idartinib is among the CSF-1R inhibitors with 
the most extensive clinical development pro-
grams. Pexidartinib is studied in glioblastoma 
multiforme, c-kit mutated melanoma, prostate 
cancer, neurofibroma, sarcoma, lymphoma, and 
leukemias. With the exception of patients with 
pigmented villonodular synovitis (PVNS) or ten-
osynovial giant cell tumors (TGCT, see below), 
single agent activity of pexidartinib is very mod-
est. Therefore, CSF-1R inhibitors will likely pro-
vide the most promise in rational combinations 
with other agents. Preclinical data supports con-
current use of pexidartinib with chemotherapy, 
radiation therapy, and immune therapy among 
other combinations.14,23–26 The current study 
found that pexidartinib given concurrently with 
paclitaxel resulted in a CR rate of 3% and a PR 
of 13%. Responses were seen in patients with 
breast, rectal, bladder, primary peritoneal, and 
ovarian cancers. The most promising signal of 
clinical activity was noted in six patients with 
platinum-resistant or -refractory epithelial 
gynecologic malignancies, with one patient expe-
riencing a CR and one having a PR with responses 
lasting for 189 and 94 days, respectively. This led 
to incorporating part 3 of the study that tested 
pexidartinib and paclitaxel combination in 
patients with platinum resistant and refractory 
ovarian cancer, and which will be reported 
separately.
One exception where therapy with CSF-1R 
inhibitor alone could result in meaningful clinical 
benefit is in the case of PVNS or TGCT; a rare 
benign proliferative disease involving large joints. 
The majority of cases harbor chromosomal trans-
locations involving the gene encoding for CSF-1 
(located on chromosome 1p13) and resulting in 
high expression of this cytokine by cells within the 
synovium. This leads to substantial recruitment 
of the mononuclear and multi-nucleated cells 
that form the bulk of the mass.27,28 Cassier and 
colleagues reported promising clinical activity of 
anti CSF1R antibody emactuzumab, with CR 
and PR rates of 7% and 79%, respectively, in 28 
patients with PVNS; 11% of patients had pro-
longed stable disease, and no patient had disease 
progression.29 In a phase II dose expansion cohort 
enrolling patients with PVNS/TGCT, pexidarti-
nib at a dose of 1000 mg daily produced PRs in 7 
of 12 patients that occurred within the first 
4 months of treatment and lasted more than 
8 months. Median PFS was not reached at the 
time the results were published.30 Given such 
promising results, a phase III study testing treat-
ment with pexidartinib or placebo in patients in 
PVNS was launched (ClinicalTrials.gov identi-
fier: NCT02371369).
In conclusion, the combination of pexidartinib 
and weekly paclitaxel was generally well-toler-
ated. No maximum tolerated dose was reached 
and RP2D for pexidartinib in combination 
with weekly paclitaxel was 1600 mg/day. 
Biomarker levels suggested that pexidartinib 
blocked CSF-1R signaling, indicating a poten-
tial for significantly mitigating macrophage 
tumor infiltration.
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